Immuneering's Pancreatic Cancer Data Fails to Impress: Stock Plunges 23% Despite Survival Claims

Immuneering (IMRX) reports 64% survival rate for Atebimetinib in pancreatic cancer trial, but shares plunge 23% as investors remain unconvinced about cross-trial comparisons and competitive threats.